Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Group 1 - Clene Inc. reported a quarterly loss of $0.78 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.49, and improved from a loss of $1.06 per share a year ago, indicating an earnings surprise of -59.18% [1] - The company posted revenues of $0.03 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 73%, and down from $0.09 million in the same quarter last year [2] - Clene shares have declined approximately 31.3% since the beginning of the year, contrasting with the S&P 500's gain of 10% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is -$0.43 on revenues of $0.1 million, and for the current fiscal year, it is -$1.69 on revenues of $0.44 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the bottom 41% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8]